Table 2.
Selected characteristics of the study participants with COX-2 genotype data
| Characteristic | Total | No Adenoma Recurrence | Adenoma Recurrence | p-value* |
|---|---|---|---|---|
| No. of subjects | 979 (100) | 546 (55.8) | 433 (44.2) | |
| Age at enrollment (mean ± SD), years | 57.6 ± 9.6 | 56.4 ± 9.7 | 59.1 ± 9.3 | <0.001 |
| Gender | ||||
| Male, No. (%) | 630 (64.4) | 330 (60.4) | 300 (69.3) | |
| Female, No. (%) | 349 (35.6) | 216 (39.6) | 133 (30.7) | 0.004 |
| Race and ethnicity, No. (%) | ||||
| Caucasian | 864 (88.3) | 473 (86.6) | 391 (90.3) | |
| African American | 45 (4.6) | 22 (4.0) | 23 (5.3) | 0.44 |
| Hispanic | 45 (4.6) | 31 (5.7) | 14 (3.2) | 0.063 |
| Asian | 18 (1.8) | 14 (2.6) | 4 (0.9) | 0.052 |
| Other | 7 (0.7) | 6 (1.1) | 1 (0.2) | 0.10 |
| Body mass index (kg/m2), No. (%) | ||||
| <25 | 309 (31.6) | 193 (35.4) | 116 (26.9) | |
| 25–30 | 455 (46.6) | 245 (45.0) | 210 (48.6) | 0.018 |
| ≥30 | 213 (21.8) | 107 (19.6) | 106 (24.5) | 0.005 |
| Current cigarette smoker, No. (%) | ||||
| No | 841 (86.2) | 487 (89.4) | 354 (82.1) | |
| Yes | 135 (13.8) | 58 (10.6) | 77 (17.9) | 0.001 |
| Current alcohol use, No. (%) | ||||
| No | 293 (31.2) | 181 (34.7) | 112 (26.7) | |
| Yes | 647 (68.8) | 340 (65.3) | 307 (73.3) | 0.008 |
| Aspirin treatment group, No. (%) | ||||
| Placebo | 329 (33.6) | 174 (31.9) | 155 (35.8) | |
| 81 mg aspirin | 330 (33.7) | 205 (37.6) | 125 (28.9) | 0.017 |
| 325 mg aspirin | 320 (32.7) | 167 (30.6) | 153 (35.3) | 0.86 |
| Folate treatment group, No. (%) | ||||
| Placebo | 449 (45.9) | 258 (47.3) | 191 (44.1) | |
| 1 mg folate | 452 (46.2) | 247 (45.2) | 205 (47.3) | 0.40 |
| Not randomized to folate | 78 (8.0) | 41 (7.5) | 37 (8.6) | 0.42 |
| Follow-up time (mean ± SD), months | 32.7 ± 3.5 | 32.6 ± 3.3 | 32.8 ± 3.8 | 0.32 |
*
Tests for comparison between group with no adenoma recurrence and group with adenoma recurrence using two sample t-test for continuous variables and Pearson chi-square test for categorical variables.